Success Metrics

Clinical Success Rate
89.5%

Based on 17 completed trials

Completion Rate
89%(17/19)
Active Trials
1(5%)
Results Posted
35%(6 trials)
Terminated
2(9%)

Phase Distribution

Ph phase_3
5
23%
Ph phase_2
1
5%
Ph phase_1
3
14%
Ph not_applicable
4
18%
Ph phase_4
9
41%

Phase Distribution

3

Early Stage

1

Mid Stage

14

Late Stage

Phase Distribution22 total trials
Phase 1Safety & dosage
3(13.6%)
Phase 2Efficacy & side effects
1(4.5%)
Phase 3Large-scale testing
5(22.7%)
Phase 4Post-market surveillance
9(40.9%)
N/ANon-phased studies
4(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.5%

17 of 19 finished

Non-Completion Rate

10.5%

2 ended early

Currently Active

1

trials recruiting

Total Trials

22

all time

Status Distribution
Active(2)
Completed(17)
Terminated(2)
Other(1)

Detailed Status

Completed17
Terminated2
unknown1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
1
Success Rate
89.5%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (13.6%)
Phase 21 (4.5%)
Phase 35 (22.7%)
Phase 49 (40.9%)
N/A4 (18.2%)

Trials by Status

unknown15%
terminated29%
active_not_recruiting15%
completed1777%
not_yet_recruiting15%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT02879409Not Applicable

HbA1c Variability in Type II Diabetes

Active Not Recruiting
NCT06085703Not Applicable

Effects of Henagliflozin on the Brain Function in T2DM Patients With Mild Cognitive Impairment: a Randomized, Parallel Controlled Clinical Trial

Completed
NCT06222476Not Applicable

Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.

Not Yet Recruiting
NCT04198948Phase 1

Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers

Completed
NCT00102466Phase 3

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Completed
NCT01991197Phase 2

Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.

Completed
NCT03705195Not Applicable

Study of Sulphonylurea Synergy With Incretins

Completed
NCT02694263Phase 4

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

Completed
NCT03467945Phase 1

Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants

Completed
NCT02610088Phase 4

Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide

Completed
NCT03313661Phase 3

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

Unknown
NCT01709305Phase 4

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

Completed
NCT01590771Phase 3

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Completed
NCT00738088Phase 4

Variation in Sulphonylurea Response in Type 2 Diabetes

Terminated
NCT02092597Phase 4

Safety Evaluation of Adverse Reactions in Diabetes

Completed
NCT03068065Phase 4

Antidiabetic Effects on Intrahepatic Fat

Completed
NCT00102388Phase 3

Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes

Completed
NCT02201602Phase 4

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Completed
NCT02777671Phase 1

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

Completed
NCT01022762Phase 4

Comparison of Repaglinide and Gliclazide in Chinese Subjects With Type 2 Diabetes Never Received Oral Antidiabetic Drug Treatment

Completed

Drug Details

Intervention Type
DRUG
Total Trials
22